Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, today announced publication of new peer-reviewed research in npj Parkinson's Disease, a ...
ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week ...
The analysis also showed that a biomarker of disease severity predicted how quickly patients declined. ... Read More The post Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA ...
Alan Alda’s first symptoms of Parkinson’s disease weren’t the typical tremors, stiffness or slow movement. It was throwing a ...
Alterity Therapeutics reported an adjusted Phase 2 analysis showing ATH434 50 mg slowed functional decline in multiple system ...
ADWEEK's Team Visionary Awards recognize the people often quietly uplifting their organizations, from the bombastic social ...
Alan Alda Opens Up About Parkinson's Diagnosis: I Can't Wish It Away ...
I had a meeting with some public health center staff the other day.It was to prepare for a study session on swallowing for ...
Alterity Therapeutics Ltd. ( ATHE) on Monday announced new analyses from its Phase 2 ATH434-201 trial in multiple system atrophy (MSA), presented at the 2026 International Congress of Parkinson's ...
- Alterity Therapeutics ATHE-5.92% reported a 52% slower functional decline in MSA MSA+1.59% patients with ATH434 at week 52, but results rely on post-hoc analysis and a narrowed dataset. - The trial ...
The Phase 2 ATH434-201 study enrolled 77 adults with MSA who received ATH434 50 mg or 75 mg twice daily, or placebo, for 12 months. The trial evaluated functional outcomes, safety, pharmacokinetics, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results